Antibodies for bioanalysis and drug monitoring of rituximab and biosimilars

Develop highly selective and sensitive PK and ADA assays for rituximab (Rituxan, MabThera) using our range of ready-made anti-idiotypic antibodies.

  • Recombinant inhibitory antibodies specific to rituximab
  • Rat anti-rituximab clone MB2 A4 for ELISA and flow cytometry
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Rituximab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Rituximab

Inhibitory

Type 1

MCA2260
MCA2260P
MCA2260F

MB2 A4

Rat IgG2a

HRP

FITC

N/A

PK bridging ELISA

Flow cytometry

Order MCA2260
Order MCA2260P
Order MCA2260F

HCA061
HCA061P

AbD02842

Fab-dHLX-MH1

HRP

4.9

PK bridging ELISA

Order HCA061
Order HCA061P

HCA062
HCA062P

AbD02844

Fab-dHLX-MH1

HRP

10.0

PK bridging ELISA

Order HCA062
Order HCA062P

HCA186

AbD18423

Fab-FH2

0.13

PK bridging ELISA

Order HCA186

HCA201

AbD18423_hIgG1

hIgG1

0.13

PK bridging ELISA

ADA control

Order HCA201

* Affinity measured in the monovalent Fab format
1 Bivalent Fab antibody, double Helix Loop Helix motif dimerization domain, Myc- and His-6-tags
2 Monovalent Fab antibody DYKDDDDK- and His-6-tags


Anti-Rituximab Inhibitory Antibodies (Type 1)

Type 1 anti-rituximab antibodies inhibit the binding of the drug rituximab to its target, the B cell surface marker CD20. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug, and for flow cytometry assays. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


ELISA Protocols to Get You Started

PK Bridging ELISA


PK assay, bridging format, using rituximab antibody

Fig. 1. Rituximab PK bridging ELISA using antibodies HCA186 and MCA2260P.

Pharmacokinetic (PK) Assay

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


ADA Bridging ELISA


ADA assay, bridging, format using Rituximab antibody

Fig. 2. Rituximab ADA bridging ELISA using antibody HCA201.

Anti-Drug Antibody (ADA) Assay – Bridging ELISA

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.